Mesa Laboratories, Inc. Revises Earnings Announcement date for Unaudited Fourth Quarter and Full Fiscal Year 2024 Results

Rhea-AI Summary

Mesa Laboratories (NASDAQ: MLAB) announced a delay in issuing its unaudited fourth quarter and full fiscal year 2024 financial results, initially scheduled for today. The delay is due to the finalization of year-end audit calculations and technical accounting for previously announced impairments in its Clinical Genomics and Biopharmaceutical Development divisions, as well as purchase accounting for GKE's acquisition. The Form 10-K filing deadline with the SEC is June 14, 2024. Mesa Laboratories is a global leader in life sciences tools and quality control solutions for regulated pharmaceutical, healthcare, and medical device industries.

Positive

• Mesa Laboratories is recognized as a global leader in life sciences tools and quality control solutions.
• The company provides critical products and services enhancing product integrity and safety in the pharmaceutical, healthcare, and medical device industries.
• The company is actively working to finalize its year-end audit, demonstrating its commitment to accuracy and transparency.

Negative

• The delay in issuing financial results may cause investor uncertainty and affect stock performance.
• The need to finalize calculations for impairments of long-lived assets and goodwill indicates financial challenges in Clinical Genomics and Biopharmaceutical Development divisions.
• The delayed earnings announcement and reliance on purchase accounting for GKE's acquisition may signal potential financial complications.

LAKEWOOD, Colo., May 31, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (“Mesa”) (NASDAQ:MLAB) will not issue its 2024 financial results for the fourth quarter and the fiscal year ending March 31, 2024 today as previously communicated. The earnings announcement has been delayed as we work to finalize our year end audit which is focused on finalizing the calculations and technical accounting for previously-announced impairments of long-lived assets and goodwill related to our Clinical Genomics and Biopharmaceutical Development divisions and the purchase accounting associated with the acquisition of GKE.

Mesa’s Form 10-K filing deadline with the SEC is June 14, 2024.

About Mesa Laboratories, Inc.

Mesa is a global leader in the design and manufacture of life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world.

For more information about the Company, please visit our website at www.mesalabs.com.

FAQ

Why did Mesa Laboratories delay its Q4 and full fiscal year 2024 financial results?

Mesa Laboratories delayed its Q4 and full fiscal year 2024 financial results to finalize year-end audit calculations and technical accounting for impairments and the acquisition of GKE.

When is the new deadline for Mesa Laboratories to file its Form 10-K?

Mesa Laboratories' new deadline to file its Form 10-K with the SEC is June 14, 2024.

What divisions are affected by the impairments at Mesa Laboratories?

The Clinical Genomics and Biopharmaceutical Development divisions at Mesa Laboratories are affected by the impairments.

What is Mesa Laboratories' stock symbol?

Mesa Laboratories' stock symbol is MLAB.

What industries does Mesa Laboratories serve?

Mesa Laboratories serves the pharmaceutical, healthcare, and medical device industries with life sciences tools and quality control solutions.